Literature DB >> 15459216

Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status.

Christian Haslinger1, Norbert Schweifer, Stephan Stilgenbauer, Hartmut Döhner, Peter Lichter, Norbert Kraut, Christian Stratowa, Roger Abseher.   

Abstract

PURPOSE: Genomic aberrations and mutational status of the immunoglobulin variable heavy chain (VH) gene have been shown to be among the most important predictors for outcome in patients with B-cell chronic lymphocytic leukemia (B-CLL). In this study, we report on differential gene expression patterns that are characteristic for genetically defined B-CLL subtypes.
MATERIALS AND METHODS: One hundred genetically well-characterized B-CLL samples, together with 11 healthy control samples, were analyzed using oligonucleotide arrays, which test for the expression of some 12,000 human genes.
RESULTS: Aiming at microarray-based subclassification, class predictors were constructed using sets of differentially expressed genes, which yielded in zero or low misclassification rates. Furthermore, a significant number of the differentially expressed genes clustered in chromosomal regions affected by the respective genomic losses/gains. Deletions affecting chromosome bands 11q22-q23 and 17p13 led to a reduced expression of the corresponding genes, such as ATM and p53, while trisomy 12 resulted in the upregulation of genes mapping to chromosome arm 12q. Using an unsupervised analysis algorithm, expression profiling allowed partitioning into predominantly VH-mutated versus unmutated patient groups; however, association of the expression profile with the VH mutational status could only be detected in male patients.
CONCLUSION: The finding that the most significantly differentially expressed genes are located in the corresponding aberrant chromosomal regions indicates that a gene dosage effect may exert a pathogenic role in B-CLL. The significant difference in the partitioning of male and female B-CLL samples suggests that the genomic signature for the VH mutational status might be sex-related.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15459216     DOI: 10.1200/JCO.2004.12.133

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  69 in total

1.  Suppression of survival signalling pathways by the phosphatase PHLPP.

Authors:  Audrey K O'Neill; Matthew J Niederst; Alexandra C Newton
Journal:  FEBS J       Date:  2012-03-16       Impact factor: 5.542

2.  NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL.

Authors:  Ilaria Del Giudice; Davide Rossi; Sabina Chiaretti; Marilisa Marinelli; Simona Tavolaro; Sara Gabrielli; Luca Laurenti; Roberto Marasca; Silvia Rasi; Marco Fangazio; Anna Guarini; Gianluca Gaidano; Robin Foà
Journal:  Haematologica       Date:  2011-12-29       Impact factor: 9.941

3.  Clinical proteomics: present and future prospects.

Authors:  Nicole M Verrills
Journal:  Clin Biochem Rev       Date:  2006-05

4.  Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination.

Authors:  David Furman; Boris P Hejblum; Noah Simon; Vladimir Jojic; Cornelia L Dekker; Rodolphe Thiébaut; Robert J Tibshirani; Mark M Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-23       Impact factor: 11.205

5.  CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes.

Authors:  David Gonzalez; Monica Else; Dorte Wren; Monica Usai; Anne Mette Buhl; Anton Parker; David Oscier; Gareth Morgan; Daniel Catovsky
Journal:  Haematologica       Date:  2012-08-16       Impact factor: 9.941

6.  SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL.

Authors:  Rodrigo Proto-Siqueira; Rodrigo A Panepucci; Francisco P Careta; Abigail Lee; Andrew Clear; Kelly Morris; Carolyn Owen; Edgar G Rizzatti; Wilson A Silva; Roberto P Falcão; Marco A Zago; John G Gribben
Journal:  Blood       Date:  2008-04-23       Impact factor: 22.113

7.  Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia.

Authors:  Dirk Kienle; Axel Benner; Carolin Läufle; Dirk Winkler; Christof Schneider; Andreas Bühler; Thorsten Zenz; Annett Habermann; Ulrich Jäger; Peter Lichter; Riccardo Dalla-Favera; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

Review 8.  HtrA serine proteases as potential therapeutic targets in cancer.

Authors:  Jeremy Chien; Mara Campioni; Viji Shridhar; Alfonso Baldi
Journal:  Curr Cancer Drug Targets       Date:  2009-06       Impact factor: 3.428

9.  Concomitant heterochromatinisation and down-regulation of gene expression unveils epigenetic silencing of RELB in an aggressive subset of chronic lymphocytic leukemia in males.

Authors:  Jean-Brice Marteau; Odile Rigaud; Thibaut Brugat; Nathalie Gault; Laurent Vallat; Mogens Kruhoffer; Torben F Orntoft; Florence Nguyen-Khac; Sylvie Chevillard; Hélène Merle-Beral; Jozo Delic
Journal:  BMC Med Genomics       Date:  2010-11-10       Impact factor: 3.063

10.  The use of knockout mice reveals a synergistic role of the Vav1 and Rasgrf2 gene deficiencies in lymphomagenesis and metastasis.

Authors:  Sergio Ruiz; Eugenio Santos; Xosé R Bustelo
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.